ABSTRACT
To determine the efficacy and safety of subconjuctival injection of mitomycin C versus daunorubicin for treatment of pterygium. This randomized double blind placebo-controlled clinical trial included 54 eyes of 36 patients with pterygium who were referred to Al-Zahra Hospital, Zahedan-Iran in 2004. Eyes were randomly assigned to three groups including mitomycin C, daunorubicin or placebo. The injection was performed subconjuctivally at limbus under the pterygium. Patients were examined before and one month after injection. Change in symptoms and size reduction of pterygia and complications were compared among the three groups. There was no statistically significant difference between the three groups in terms of age and primary pterygium size. Post-injection reduction in symptoms and pterygium size had no significant difference among the three groups. Post-njection complication rates were 72.2%, 93.3% and 40% in the mitomycin, daunorubicin and placebo groups, respectively. Serious complications were not seen in any group. Subconjuctival injection of mitomycin C and daunorubicin for treatment of pterygium is relatively safe, but has little effect in reducing symptoms and pterygium size
ABSTRACT
Psoriasis is a chronic inflammatory skin disorder. Several studies have indicated that psoriatic patients have higher risk for coronary heart disease and few studies focused on lipid profiles which are important in the pathogenesis of coronary heart disease. This study was designed to investigate the relationship between psoriasis and hyperlipidemia. In this case control study lipid parameters [cholesterol, Triglycerid, High density lipoprotein, Low density lipoprotein, Very low density lipoprotein] of 40 patients with moderate and severe psoriasis [study group] were compared with 40 healthy persons [control group]. Study group matched the control group considering age, sex, BMI, hypertension, habit of smoking and alcohol and body activities. In both groups 19 male and 21 female with a mean age of 37 +/- 16 were studied. Mean lipid level in case group including: TG, chol, HDL, LDL, VLDL, was respectively 105/4 +/- 48/5, 180/52 +/- 39/10, 41/22 +/- 1/87, 117/85 +/- 35/52, 21/57 +/- 10/59 and in control group was 103/8 +/- 47/95,173/92 +/- 33/41, 39/25 +/- 9/78 114 +/- 36/07, 20/62 +/- 9/57, which showed no significant difference between the two groups [p>0.05]. According to these results it seems that we don't need to investigate lipid profiles in psoriatic patients